First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma PatientsTreated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

Francesco Annibale D'Amore, S Leppä, M Gomes da Silva, T Relander, Peter De Nully Brown, E Weidmann, GF Lauritzsen, A Pezzutto, A Van Hoof, M Van Gelder, J Doorduijn, KL Wu, JC Kluin-Nelemans, PJ Lugtenburg, M Jankovska, M Merup, U-M Fagerli, J Walewski, H Hagberg, JM MarizPB Hansen, T Nösslinger, A Janssens, L Brandefors, H Demuynck, MR Schaafsma, Ilse Christiansen, D Salek, S Jyrkkiö, V Prochazka, J Zijlstra, L Böhmer, R Greil, W Stevens, R Fijnheer, M van Marwijk, M Grube, L Trümper, G Wulf, B Altmann, M Ziepert, M Loeffler, E Jantunen, G Hopfinger, E Van den Neste, H Toldbod

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

OriginalsprogEngelsk
TidsskriftBlood
Vol/bind120
ISSN0006-4971
StatusUdgivet - 1 nov. 2012
Udgivet eksterntJa

Citationsformater